Endocrine Abstracts

This research was designed to estimate effectiveness and safety of Lindaxa in treatment of obesity associated with IGT and arterial hypertension. Thus, 20 women (mean age 37.9 years-old) were treated with complex therapy including traditional therapy (diet, physical exercises, dhydration, metabolic and symptomatic treatment) including Lindaxa with dosage of 10–15 mg/day once daily during 6 months. Physical exercises were determined individually according to BMI and metabolic disorders.

Clinical evaluation included brain MRI, Echocardiography, US imaging of abdominal cavity, lipids and carbohydrates metabolism (cholesterol, LDL, HDL, triglycerides, β-lipoproteids, fasting glucose concentration). Besides, BMI, waist circumference, OGTT were evaluated in women with obesity. Control tests were conducted before treatment and after 3, 6 months intervals with evaluation of BMI, waist circumference, lipids profile, glucose levels and OGTT.

Women with arterial hypertension (eight women with mean blood pressure of 145/90 mmHg) treated with Lindaxa (sibutramine) we recommended hypertension and heart rate monitoring every 2 weeks during first 3 months of therapy and monthly during following 3 months of treatment. Results showed systolic blood pressure (SBP) increase by 2.0 mmHg whereas diastolic blood pressure (DBP) elevated by 1.6 mmHg and heart rate increased by 2–5 beats per minute during the first month of therapy, however, with body mass decrease with the Lindaxa therapy blood pressure reliably decreased during the first month of therapy. Thus, after 6 months of treatment SBP decreased by 3.4 mmHg, while DBP reduced by 2.4 mmHg.

Comparative evaluation of metabolic data in obese patients treated with Lindaxa after 6 months showed OGTT change from 5.2–11.1–5.6- to 4.8–5.8–4.7 mmol/l, decrease in cholesterol levels from 5.2 to 4.6, while β-lipoproteids and LDL decreased from 0.62 and 3.1 to 0.54 and 2.4 respectively; triglycerides reduced from 2.03 to 1.35 while HDL increased from 1.69 to 2.2. The more patient lost weight the more evident improvement in above mentioned tests.

After 6 months of Lindaxa therapy weight loss achieved significant reliable reduction with mean 11.0 kg, where mean body weight reduced from 84.5 to 73.5 kg and BMI decreased to 27.8 kg/m². Two patients who showed no change in body weight developed resistance to the treatment, however, IGT had positive dynamics.

Treatment with Lindaxa improves lipids profile, reduces body mass, decreases elevated blood pressure both systolic and diastolic, and glucose tolerance. Moreover, Lindaxa shows positive effect on lipids metabolism, which is important factor in treatment and reducing cardiovascular risk in patients with obesity.